Acquisition Completed
Amgen acquisition of Dark Blue Therapeutics
US$840m equity value
Announced 6 Jan 2026
Advisers
Dark Blue Therapeutics
Target
- Financial adviser
Amgen
Acquirer
Not disclosed
- Target
- Dark Blue Therapeutics
- Acquirer
- Amgen
- Target based in
- United Kingdom
- Buyer based in
- United States
- Completed
- 6 Jan 2026
- Sector
- Biotech
- Tags
- Biotech, Oncology, Drug Development
In the league tables
Similar deals
- GSK acquisition of trispecific T cell-engager (TCE) asset Sep 2026 · US$750m · Biotech
- Treeline Biosciences and Standard BioTools merger Jun 2026 · US$460m · Biotech
- Novartis acquisition of Pikavation Mar 2026 · US$2bn · Biotech
- Eli Lilly and Company acquisition of Ajax Therapeutics Apr 2026 · US$2.3bn · Biotech
- Eli Lilly and Company acquisition of CrossBridge Bio Apr 2026 · US$300m · Biotech
Sources
- 6 Jan 2026 Press release (PR Newswire), Dark Blue Therapeutics acquired by Amgen for up to $840 million prnewswire.com
- 7 Jan 2026 Goodwin Advises Dark Blue Therapeutics on $840 Million Acquisition goodwinlaw.com

